Tuning mitochondrial fate to disarm leukemic stem cells.

mechanistic explanation for infection risk with BCMA-targeted bispecific antibodies.These insights should inform individualized prophylaxis and guide the design of safer immunotherapy regimens in combination.As we embrace the promise of bispecific antibodies for all patients, balancing efficacy with immune competence will be key to optimizing patient outcomes.